Long-acting glucagon-like peptide-1 receptor agonist-status December 2018

Affiliations

Editorial

Jens Juul Holst. Ann Transl Med. 2019 Mar.

. 2019 Mar;7(5):83.

doi: 10.21037/atm.2019.01.09.

¹ Department of Biomedical Sciences and NNF center for Basic Metabolic Research, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has appeared on advisory boards for NovoNordisk.

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A; SUSTAIN 7 investigators. Pratley RE, et al. Lancet Diabetes Endocrinol. 2018 Apr;6(4):275-286. doi: 10.1016/S2213-8587(18)30024-X. Epub 2018 Feb 1. Lancet Diabetes Endocrinol. 2018. PMID: 29397376 Clinical Trial.

1. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669-701. 10.2337/dci18-0033 - DOI - PMC - PubMed
1. Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiol Rev 2007;87:1409-39. 10.1152/physrev.00034.2006 - DOI - PubMed
1. Zhang Y, Sun B, Feng D, et al. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 2017;546:248-53. 10.1038/nature22394 - DOI - PMC - PubMed
1. Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest 2017;127:4217-27. 10.1172/JCI97233 - DOI - PMC - PubMed
1. Kjems LL, Holst JJ, Volund A, et al. The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on beta-Cell Sensitivity in Type 2 and Nondiabetic Subjects. Diabetes 2003;52:380-6. 10.2337/diabetes.52.2.380 - DOI - PubMed